Find Paid Research Studies in Atlanta, Georgia

Browse Locations ... United States» ... Georgia» ... Atlanta

Exparel vs. Standard Bupivicaine for Abdominoplasty

Condition: Pain, Postoperative
Interventions: Drug: Liposomal Injection Bupivacaine (Exparel); Drug: Standard bupivicaine
Sponsors: Emory University; Emory University
Not yet recruiting - verified May 2013
Safety and Efficacy of a Steroid-free, Calcineurin Inhibitor-free, Belatacept-based Immunosuppressive Regimen

Conditions: Kidney Transplantation; Transplantation
Interventions: Biological: Anti-thymocyte Globulin (Rabbit); Biological: Belatacept; Drug: Methylprednisolone; Biological: basiliximab; Drug: Mycophenolate Acid; Drug: Tacrolimus
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Clinical Trials in Organ Transplantation (CTOT)
Not yet recruiting - verified May 2013
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
Phase 2 Study of SOF+GS-5816 in Treatment Naive Subjects With Chronic HCV

Condition: Hepatitis C
Intervention: Drug: SOF in combination with GS-5816
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure

Condition: Congestive Heart Failure
Interventions: Drug: D-ribose; Other: Placebo
Sponsors: RiboCor, Inc.; RiboCor, Inc.
Not yet recruiting - verified May 2013
Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

Condition: Type 2 Diabetes
Interventions: Drug: Sitagliptin + glargine; Drug: Basal Bolus; Drug: Metformin and sitagliptin; Drug: Metformin and sitagliptin + glargine 50%; Drug: Metformin and sitagliptin + glargine 80%
Sponsors: Emory University; Emory University
Not yet recruiting - verified May 2013
Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Subjects With Type 1 Diabetes (T1DM)

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Drug: Pre-commercial formulation of Hylenex recombinant (hyaluronidase human injection); Procedure: Preadministration of commercial Hylenex® recombinant (hyaluronidase human injection); Procedure: Preadministration of pre-commercial Hylenex recombinant (hyaluronidase human injection); Device: Continuous Subcutaneous Insulin Infusion (CSII) via insulin infusion pumps
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified May 2013
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Condition: Generalized Anxiety Disorder
Interventions: Drug: Placebo; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Not yet recruiting - verified April 2013
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

Condition: Major Depressive Disorder
Intervention: Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Not yet recruiting - verified April 2013
Study to Evaluate Safety & Efficacy of WC3011 in Postmenopausal Women With Dyspareunia

Condition: Vulvovaginal Atrophy
Interventions: Drug: Estradiol Vaginal Gel; Drug: Vehicle
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified April 2013
The Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo; Drug: Rifaximin
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified April 2013
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Condition: Multiple Myeloma
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AbbVie
Recruiting - verified April 2013
Photodynamic Therapy (PDT) Oncology Registry

Conditions: Lung Cancer; Esophageal
Intervention:
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Pinnacle Biologics Inc.
Recruiting - verified April 2013
The KP Personal Shopper: A Pilot to Improve the Impact of Dietary Advice

Conditions: Overweight; Obesity
Interventions: Behavioral: KP Personal Shopper Visits; Behavioral: In-Office Dietitian Visits
Sponsors: Kaiser Permanente; Kaiser Permanente
Not yet recruiting - verified May 2013
A Study of LY3002813 in Participants With Alzheimer's Disease

Condition: Alzheimer Disease
Interventions: Biological: LY3002813-IV; Biological: LY3002183-SC; Drug: Placebo-IV
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men

Conditions: HIV; Gonorrhea; Chlamydia
Interventions: Behavioral: Keep It Up!; Behavioral: HIV Knowledge Control
Sponsors: Northwestern University; Northwestern University; National Institute on Drug Abuse (NIDA); Emory University; Hunter College
Recruiting - verified May 2013
Phase Analysis and Obstructive CAD on Rubidium PET

Condition: Coronary Artery Disease
Intervention: Drug: Regadenoson
Sponsors: Emory University; Emory University
Not yet recruiting - verified April 2013
Controlling and Lowering Blood Pressure With The MOBIUSHD™

Condition: Hypertension
Intervention: Device: MobiusHD™
Sponsors: Vascular Dynamics, Inc.; Vascular Dynamics, Inc.
Recruiting - verified May 2013
Safety and Efficacy of Intranasal and Topical Mupirocin in Eradicating Colonization With Staphylococcus Aureus (SA) in Critically Ill Infants - a Phase 2, Multi-Center, Open Label, Randomized Trial

Condition: Staphylococcus Aureus
Interventions: Drug: Mupirocin ointment; Drug: Mupirocin cream
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified March 2013
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013
A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia

Condition: Primary Hypercholesterolemia or Mixed Dyslipidemia
Intervention: Device: AMG 145
Sponsors: Amgen; Amgen
Not yet recruiting - verified May 2013
Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Conditions: HIV; HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas

Condition: Basal Cell Carcinoma
Interventions: Drug: vismodegib; Drug: vismodegib; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

Condition: Heart Failure
Interventions: Drug: BAY94-8862; Drug: Placebo; Drug: Inspra (eplerenone)
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2013
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076 AM1)

Condition: Osteoporosis
Interventions: Drug: odanacatib; Other: placebo to odanacatib
Sponsors: Merck; Merck
Recruiting - verified May 2013
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia

Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551); Drug: Aerosolized Placebo
Sponsors: Bayer; Bayer; Nektar Therapeutics; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Condition: Spasticity
Intervention: Drug: Baclofen
Sponsors: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries Limited
Recruiting - verified April 2013
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Condition: Sickle Cell Disease
Interventions: Drug: Prasugrel; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified May 2013
Generic Database of Moderate Preterm Infants

Conditions: Infant, Newborn; Infant, Moderate Preterm
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified February 2013
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified May 2013
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Condition: Hypertension
Interventions: Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Living Well Project

Condition: Acquired Immunodeficiency Syndrome (AIDS)
Interventions: Behavioral: AIDS EPC Package plus MI; Other: Standard of Care (SOC)
Sponsors: Emory University; Emory University; Grady Health System
Not yet recruiting - verified May 2013
Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Ibrutinib; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

Condition: Plaque Psoriasis
Interventions: Drug: Ixekizumab Auto-Injector; Drug: Ixekizumab Prefilled Syringe
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Placebo (administered subcutaneously); Drug: Ezetimibe; Other: Placebo (administered orally)
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: leucovorin; Drug: 5-fluorouracil; Drug: irinotecan; Drug: oxaliplatin; Drug: capecitabine [Xeloda]; Drug: fluoropyrimidine-based chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease
Intervention: Drug: Saxagliptin
Sponsors: Duke University; Duke University
Recruiting - verified May 2013
Procurement of Human Specimens for the Evaluation of Early Markers of Sepsis

Condition: Infection
Intervention:
Sponsors: Abbott Diagnostics Division; Abbott Diagnostics Division
Recruiting - verified April 2013
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

Condition: Asthma
Interventions: Drug: Albuterol Spiromax® 90 mcg/inhalation; Drug: Placebo Spiromax
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified April 2013
Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

Condition: Triple Negative Breast Cancer
Interventions: Drug: Tivozanib Hydrochloride; Drug: paclitaxel
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.; Astellas Pharma Inc
Recruiting - verified April 2013
MAESTRO (Macitentan in Eisenmenger Syndrome To Restore Exercise Capacity)

Condition: Eisenmenger Syndrome
Interventions: Drug: Macitentan 10 mg, oral tablet, to be taken once daily.; Drug: Matching placebo oral tablet, to be taken once daily.
Sponsors: Actelion; Actelion
Recruiting - verified May 2013
MAESTRO-OL: Macitentan in Eisenmenger Syndrome To Restore Exercise Capacity (Open-Label)

Condition: Eisenmenger Syndrome
Intervention: Drug: Macitentan 10 mg tablet, once daily.
Sponsors: Actelion; Actelion
Not yet recruiting - verified May 2013
Open-Label Safety & Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cystinosis

Condition: Cystinosis
Interventions: Drug: RP103 Q12H; Drug: Cystagon Q6H
Sponsors: Raptor Therapeutics Inc.; Raptor Therapeutics Inc.
Recruiting - verified April 2013
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013
Safety and Efficacy of Bioabsorbable Drug-Eluting Sinus Implant for Chronic Sinusitis

Condition: Chronic Sinusitis
Interventions: Drug: S8 sinus implant; Drug: continued nasal steroid spray
Sponsors: Intersect ENT; Intersect ENT
Recruiting - verified May 2013
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

Condition: Reduction of Hypertrophic Skin Scarring
Interventions: Drug: PF-06473871; Drug: PF-06473871
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: tivantinib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Maternal and Neurodevelopmental Outcomes of in Utero Antiepileptic Drug (AED) Exposure

Conditions: Epilepsy; Pregnancy
Intervention:
Sponsors: Emory University; Emory University; The EMMES Corporation
Recruiting - verified April 2013
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified April 2013
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified May 2013
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127-placebo: 8-week treatment; Drug: Ribavirin: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Ribavirin-placebo: 8-week treatment; Drug: Faldaprevir-placebo: 8-week treatment; Drug: Faldaprevir: 16-week treatment; Drug: Ribavirin: 16-week treatment; Drug: RBV: 24-week treatment; Drug: BI 207127: 16-week treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
RITHM - Resonance Imaging Trial for Heart Biomarkers in Adolescent/Young (AYA) Cancer Survivors

Conditions: if Aortic Stiffness; Myocardial Wall Strain
Intervention:
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified May 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Barostim HOPE4HF (Hope for Heart Failure) Study

Condition: Heart Failure
Intervention: Device: Barostim Neo system
Sponsors: CVRx, Inc.; CVRx, Inc.
Recruiting - verified April 2013
A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: PCI-32765; Drug: Chlorambucil
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified May 2013
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Condition: Atrial Fibrillation
Interventions: Drug: rivaroxaban; Drug: uninterrupted vitamin K antagonist (VKA)
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC
Recruiting - verified May 2013
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Condition: Alzheimer's Disease
Interventions: Drug: PF-05212377 (SAM-760); Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Versartis Trial in Children to Assess Long-Acting Growth Hormone

Condition: Pediatric Growth Hormone Deficiency
Intervention: Drug: Experimental: VRS-317
Sponsors: Versartis Inc.; Versartis Inc.
Recruiting - verified May 2013
Standard Radiation Therapy Combined With High Dose, Ablative Radiation in Patients With Advanced Lung Cancer That Cannot be Removed by Surgery

Conditions: Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: stereotactic body radiation therapy; Drug: carboplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Emory University; Emory University; National Cancer Institute (NCI)
Recruiting - verified May 2013
Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Conditions: Recurrent Melanoma; Recurrent Thyroid Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified May 2013
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)

Condition: Hodgkin Disease
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

Condition: Cystic Fibrosis
Intervention: Drug: ivacaftor
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013
A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia

Condition: Biliary Atresia
Intervention: Drug: Intravenous immunoglobulin (IVIG)
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified May 2013
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

Condition: High Risk Acute Myeloid Leukemia
Interventions: Drug: CPX-351; Drug: 7+3 (cytarabine and daunorubicin)
Sponsors: Celator Pharmaceuticals; Celator Pharmaceuticals; The Leukemia and Lymphoma Society
Recruiting - verified May 2013
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

Condition: Cystic Fibrosis
Interventions: Biological: KB001-A; Biological: Placebo Comparator
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified May 2013
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Condition: Psoriasis, Arthritic
Interventions: Drug: ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Conditions: For Donors:; Related Donors Donating PBSC to a Family Member; For Recipients:; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Chronic Lymphocytic Leukemia
Intervention: Drug: Plerixafor
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Genzyme; Sanofi
Recruiting - verified May 2013
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin; Drug: placebo
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified May 2013
Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified May 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Clinical Efficacy Study Comparing VisionScope Imaging (VSI) to Magnetic Resonance Imaging (MRI) in Injuries of the Knee

Conditions: Meniscus Tears; Loose Bodies; Articular Osteoarthritis; Articular or Capsular Trauma
Intervention: Procedure: VisionScope Imaging (VSI) Exam
Sponsors: VisionScope Technologies; VisionScope Technologies
Recruiting - verified April 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854; Drug: NBI-98854; Drug: Placebo
Sponsors: Neurocrine Biosciences; Neurocrine Biosciences
Recruiting - verified May 2013
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Condition: Narcolepsy
Interventions: Drug: ADX-N05; Drug: Placebo
Sponsors: Aerial BioPharma, LLC; Aerial BioPharma, LLC
Recruiting - verified May 2013
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: MK-3102 Placebo; Drug: Glimepiride; Drug: Glimepiride Placebo; Drug: Metformin; Drug: Insulin Glargine
Sponsors: Merck; Merck
Recruiting - verified April 2013
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

Condition: Schizophrenia
Intervention: Drug: Aripiprazole IM Depot
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; H. Lundbeck A/S; Otsuka America Pharmaceutical
Recruiting - verified May 2013
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin/Simvastatin FDC; Drug: Sitagliptin; Drug: Simvastatin; Drug: Placebo to sitagliptin; Drug: Placebo to simvastatin; Drug: Placebo to Sitagliptin/Simvastatin FDC; Drug: Metformin; Drug: Glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2013
Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation

Condition: Paroxysmal Atrial Fibrillation (PAF)
Interventions: Device: Blazer Open-Irrigated Ablation Catheter (Boston Scientific); Device: FDA Approved Open-Irrigated Ablation Catheter
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Recruiting - verified May 2013
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide; Drug: liraglutide; Drug: exenatide
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Condition: Bipolar 1 Disorder
Interventions: Drug: ELND005; Drug: Lamotrigine; Drug: Valproic acid; Drug: Placebo
Sponsors: Elan Pharmaceuticals; Elan Pharma International Limited; Elan Pharmaceuticals
Recruiting - verified May 2013
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

Condition: Ischemic Dilated Cardiomyopathy (IDCM)
Interventions: Biological: ixmyelocel-T; Other: Vehicle Control
Sponsors: Aastrom Biosciences; Aastrom Biosciences
Recruiting - verified May 2013
Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC

Condition: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Everolimus
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Co. Ltd
Recruiting - verified May 2013
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Condition: Schizophrenia
Intervention: Drug: Aripiprazole IM Depot
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; H. Lundbeck A/S; Otsuka America Pharmaceutical
Recruiting - verified May 2013
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Bevacizumab [Avastin]; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727) (ODYSSEY Outcomes)

Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

Condition: Infusion Reactions
Intervention: Drug: unlicensed cord blood units
Sponsors: New York Blood Center; New York Blood Center
Recruiting - verified May 2013
Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

Condition: Treatment Resistant Depression
Interventions: Device: Low Frequency Magnetic Stimulation (LFMS); Device: Sham LFMS
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Mental Health (NIMH); Yale University; Mount Sinai School of Medicine; University of Texas Southwestern Medical Center; University of Alabama at Birmingham; Emory University
Recruiting - verified May 2013
The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis

Condition: Acute Appendicitis
Intervention:
Sponsors: Venaxis, Inc.; Venaxis, Inc.
Recruiting - verified May 2013
Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy

Condition: Lumbosacral Radiculopathy
Interventions: Drug: z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified May 2013
Efficacy and Safety Study of RPC1063 in Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: RPC1063; Drug: placebo
Sponsors: Receptos, Inc.; Receptos, Inc.
Recruiting - verified May 2013
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified May 2013
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Condition: Cystic Fibrosis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified July 2012
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer

Conditions: Extensive Stage Small Cell Lung Cancer; Large Cell Lung Cancer; Metastatic Carcinoma of Unknown Primary; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary
Interventions: Drug: veliparib; Other: placebo; Drug: etoposide; Drug: cisplatin; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Reiterative Development and Evaluation Study of OSA Therapy System

Condition: Obstructive Sleep Apnea
Intervention:
Sponsors: ApniCure, Inc.; ApniCure, Inc.
Recruiting - verified May 2013
Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib and HU-placebo; Drug: HU and ruxolitinib-placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant; Drug: BKM120; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Condition: HIV Infections
Interventions: Drug: MK-1439; Drug: Efavirenz; Drug: TRUVADA®
Sponsors: Merck; Merck
Recruiting - verified May 2013
An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis

Conditions: Primary Myelofibrosis; Post Polycythemia Vera Fibrosis; Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: INCB039110
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

Condition: Narcolepsy
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
A Study of Ketamine in Patients With Treatment-resistant Depression

Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Ketamine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Osteonecrosis of the Jaw (ONJ) Case Registry

Condition: Osteonecrosis of the Jaw (ONJ)
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified April 2013
KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Condition: Adult T-cell Leukemia-Lymphoma
Interventions: Biological: KW-0761; Drug: investigator's choice (pralatrexate; gemcitabine/oxaliplatin; dexamethasone/cisplatin/cytarabine))
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified May 2013
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified April 2013
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013
Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

Condition: Female Orgasmic Disorder
Interventions: Drug: Placebo; Drug: Low dose TBS-2; Drug: Medium dose TBS-2; Drug: High dose TBS-2
Sponsors: Trimel Biopharma SRL; Trimel Biopharma SRL
Recruiting - verified May 2013
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Drug: Bendamustine hydrochloride; Drug: Rituximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Study of MLN8237 in Combination With Irinotecan and Temozolomide

Condition: Neuroblastoma
Interventions: Drug: MLN8237; Drug: Irinotecan; Drug: Temozolomide
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium
Recruiting - verified April 2013
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Condition: Hypercholesterolemia
Interventions: Drug: PBO; Drug: 200mg PF-04950615 (RN316); Drug: 300mg PF-04950615 (RN316); Drug: PBO; Drug: PF-04950615; Drug: PF-04950615; Drug: PF-04950615
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI; Biological: ch14.18-UTC; Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Biological: Aldesleukin (IL-2); Drug: Isotretinoin
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified April 2013
Neuroblastoma Biology Study

Condition: Neuroblastoma
Intervention:
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium
Recruiting - verified April 2013
Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

Conditions: Ulcerative Colitis; Left-sided Ulcerative Colitis; Distal Ulcerative Colitis
Interventions: Drug: Zoenasa-1:4; Drug: Mesalamine Enema
Sponsors: Altheus Therapeutics, Inc.; Altheus Therapeutics, Inc.
Recruiting - verified May 2013
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified May 2013
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

Conditions: Primary Immunodeficiency; Agammaglobulinemia; Hypogammaglobulinemia; Antibody Deficiency
Intervention: Biological: Kedrion IVIG 10%
Sponsors: Kedrion S.p.A.; Kedrion S.p.A.
Recruiting - verified May 2013
Driveline Silicone Skin Interface Registry

Condition: Driveline Heart-assisted Device Related Infection
Intervention:
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, prednisone, custirsen sodium; Drug: cabazitaxel, prednisone
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition: Smoking Cessation
Interventions: Drug: placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: BKM120 matching placebo; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

Condition: Advanced Cancer
Interventions: Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
To Evaluate the Safety, Tolerability and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) With Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: STF 115469 Foam; Drug: Vehicle Foam
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Recruiting - verified April 2013
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone; Drug: Velcade plus dexamethasone
Sponsors: Onyx Pharmaceuticals; Onyx Pharmaceuticals
Recruiting - verified May 2013
Investigating tDCS as a Treatment for Unipolar and Bipolar Depression

Conditions: Unipolar Depression; Bipolar Depression
Interventions: Device: Sham tDCS device; Device: Soterix tDCS device
Sponsors: The University of New South Wales; The University of New South Wales; Duke University; Emory University; Sheppard Pratt Health System; University of Medicine and Dentistry New Jersey; University of Texas
Recruiting - verified May 2013
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 16 Years With Bladder Overactivity Caused By A Neurological Condition

Condition: Urinary Bladder, Neurogenic
Interventions: Drug: Fesoterodine 4 mg; Drug: Fesoterodine 8 mg; Drug: Oxybutynin; Drug: Fesoterodine
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Pediatric Arthritis Study of Certolizumab Pegol

Condition: Juvenile Idiopathic Arthritis (JIA)
Intervention: Drug: Certolizumab Pegol (CZP)
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013
The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Trauma Patients

Condition: Anterior Tibial Compartment Syndrome
Intervention:
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command
Recruiting - verified May 2013
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: rifaximin; Drug: placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified January 2013
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Condition: Schizophrenia
Interventions: Drug: AMG 747; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

Condition: Magnetic Resonance Imaging
Intervention: Drug: Gadobutrol (Gadavist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM2)

Condition: Hepatitis C, Chronic
Interventions: Biological: peginterferon alfa-2a; Drug: ribavirin; Drug: boceprevir
Sponsors: Merck; Merck
Recruiting - verified May 2013
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Condition: Schizophrenia
Interventions: Drug: AMG 747; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2013
Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

Condition: Healthy
Interventions: Drug: Lacosamide (LCM); Drug: Carbamazepine Immediate Release (CBZ-IR)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PPM3 175 mg eq.; Drug: PPM3 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

Conditions: Geographic Atrophy; Age-related Macular Degeneration
Interventions: Drug: LFG316; Drug: Sham
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Condition: Hepatitis C, Chronic
Interventions: Drug: tenofovir; Drug: midazolam; Drug: BI 201335; Drug: caffeine; Drug: tolbutamide; Drug: tolbutamide; Drug: midazolam; Drug: caffeine; Drug: pegylated interferon; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 207127; Drug: ribavirin; Drug: ribavirin; Drug: ribavirin; Drug: BI 201335; Drug: BI 207127; Drug: ribavirin; Drug: pegylated interferon; Drug: caffeine; Drug: tolbutamide; Drug: BI 207127; Drug: ribavirin; Drug: midazolam; Drug: BI 201335; Drug: BI 207127
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Conditions: Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified May 2013
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Condition: Type 2 Diabetes
Interventions: Drug: "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)]; Drug: Insulin glargine, metformin, prandial insulin
Sponsors: University of Washington; University of Washington; Eli Lilly and Company; Sanofi; Bristol-Myers Squibb; DexCom, Inc.; Bayer; Medicomp; University of Texas; Department of Veterans Affairs; Biomedical Research Institute of New Mexico
Recruiting - verified May 2013
Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy

Condition: Epithelial Ovarian Cancer
Interventions: Biological: Placebo Study Agent; Biological: Cvac
Sponsors: Prima BioMed Ltd; Prima BioMed Ltd
Recruiting - verified May 2013
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Combining Lesinurad With Allopurinol in Inadequate Responders

Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

Condition: Tophaceous Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

Conditions: Chronic Myocardial Ischemia; Refractory Angina Pectoris; (Advanced) Coronary Heart Disease
Interventions: Biological: Auto-CD34+ cells; Biological: Placebo: Diluent used to suspend Auto-CD34+ cells; Other: Standard of care
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2013
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Conditions: Diffuse Large B-cell Lymphoma; Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies

Conditions: Cancer; Neoplasms; Tumors
Intervention: Drug: OSI-906 and Pemetrexed
Sponsors: Emory University; Emory University; OSI Pharmaceuticals
Not yet recruiting - verified May 2013
Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: MM-398; Drug: 5 Fluorouracil; Drug: Leucovorin
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified April 2013
AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified February 2013
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Ganetespib; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Emory University; Emory University; Multiple Myeloma Research Consortium
Recruiting - verified May 2013
Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

Condition: Cervical Dystonia
Intervention: Biological: Xeomin®
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC
Recruiting - verified April 2013
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013
ATLAS - Anti-Tweak in Lupus Nephritis Patients

Condition: Lupus Nephritis
Interventions: Drug: BIIB023; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Biogen Idec Australia Pty Ltd; Biogen Idec Research Ltd.; Biogen Idec MA Inc.
Recruiting - verified April 2013
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Merck; Merck
Recruiting - verified May 2013
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Condition: Solid Tumor
Intervention: Drug: ARQ 092
Sponsors: ArQule; ArQule
Recruiting - verified May 2013
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD treatment; Other: Standard of care (Control)
Sponsors: Vital Therapies, Inc.; Vital Therapies, Inc.
Recruiting - verified April 2013
GLORIA-AF Registry Program - Second and Third Phases

Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study Of Oral CP-690550 As A Maintenance Therapy For Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Condition: Solid Tumors
Interventions: Drug: BKM120; Drug: Everolimus
Sponsors: Emory University; Emory University; Novartis Pharmaceuticals
Recruiting - verified May 2013
Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer

Conditions: Esophageal Cancer; Neoplasms, Esophageal
Interventions: Drug: Everolimus; Drug: Paclitaxel; Drug: carboplatin; Drug: cetuximab
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified May 2013
Study of Arsenic Trioxide in Small Cell Lung Cancer

Conditions: Lung Cancer; Cancer of Lung; Pulmonary Cancer; Pulmonary Neoplasms; Carcinoma, Small Cell
Intervention: Drug: Arsenic Trioxide
Sponsors: Emory University; Emory University; Cephalon
Recruiting - verified May 2013
Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Condition: Spasticity
Interventions: Drug: Baclofen ER Capsules; Drug: Placebo GRS
Sponsors: Sun Pharma Advanced Research Company Limited; Sun Pharma Advanced Research Company Limited
Recruiting - verified April 2013
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

Condition: Depression Disorder, Major
Interventions: Drug: RO4995819; Drug: RO4995819; Drug: RO4995819; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Dalantercept
Sponsors: Acceleron Pharma, Inc.; Acceleron Pharma, Inc.
Recruiting - verified May 2013
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Pomalidomide; Drug: Dexamethasone
Sponsors: Academic Myeloma Consortium; Academic Myeloma Consortium; Criterium Inc.; Onyx Pharmaceuticals; Celgene Corporation
Recruiting - verified April 2013
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

Condition: Heart Failure
Interventions: Device: HM II (HeartMate II LVAD); Drug: OMM (Optimal Medical Management)
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Condition: Crohn's Disease
Intervention: Drug: Entocort
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified April 2013
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

Condition: Pulmonary Emphysema
Interventions: Device: Treatment plus Optimal Medical Therapy; Other: Optimal Medical Therapy
Sponsors: Aeris Therapeutics; Aeris Therapeutics
Recruiting - verified May 2013
LifeVest Post-CABG Registry

Conditions: Sudden Cardiac Death; Ventricular Fibrillation; Ventricular Tachycardia; Ventricular Dysfunction; Myocardial Ischemia
Intervention: Device: wearable defibrillator (LifeVest)
Sponsors: Zoll Medical Corporation; Zoll Medical Corporation
Recruiting - verified April 2013
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 + MCV4 + Tdap; Biological: MCV4 + Tdap + saline; Biological: rLP2086 + saline
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

Conditions: Benign Neoplasms, Brain; Brain Cancer; Brain Neoplasms, Benign; Brain Neoplasms, Malignant; Brain Tumor, Primary; Brain Tumor, Recurrent; Brain Tumors; Intracranial Neoplasms; Neoplasms, Brain; Neoplasms, Intracranial; Primary Brain Neoplasms; Primary Malignant Brain Neoplasms; Primary Malignant Brain Tumors; Gliomas; Glioblastoma
Intervention: Drug: 5-ALA (Gliolan)
Sponsors: Emory University; Emory University
Recruiting - verified May 2013
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects

Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura
Interventions: Drug: romiplostim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Safety Study of Entocort for Children With Crohn's Disease

Condition: Crohn's Disease
Intervention: Drug: Entocort
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013
Open Label Study of Long Term Evaluation Against LDL-C Trial

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified April 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

Condition: Depression Disorder, Major
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

Condition: Glioblastoma Multiforme
Intervention: Drug: Temozolomide, bevacizumab and bortezomib
Sponsors: Emory University; Emory University
Recruiting - verified May 2013
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Condition: Hepatorenal Syndrome
Interventions: Drug: 5mg Ifetroban Injection; Drug: 15mg Ifetroban Injection; Drug: 50mg Ifetroban Injection; Drug: 150mg Ifetroban Injection; Other: 5% Dextrose in Water
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified April 2013
Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Condition: Non-24-Hour Sleep-Wake Disorder
Intervention: Drug: tasimelteon
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified May 2013
Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3)

Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2013
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma

Conditions: Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin; Drug: rituximab
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection

Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
Blood Tests to Study Injury Severity and Outcome in Traumatic Brain Injury Patients

Condition: Traumatic Brain Injury
Intervention:
Sponsors: Emory University; Emory University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified April 2013
Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384 AM3)

Condition: Bipolar 1 Disorder
Interventions: Drug: asenapine; Drug: placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Conditions: Cognitive/Functional Effects; Fatigue; Neurotoxicity; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Therapy-related Toxicity; Waldenström Macroglobulinemia
Interventions: Drug: temsirolimus; Biological: rituximab; Drug: bortezomib; Drug: dexamethasone
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Condition: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Drug: STX-100; Drug: Placebo
Sponsors: Stromedix, Inc.; Stromedix, Inc.
Recruiting - verified May 2013
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Conditions: Extensive Stage Small Cell Lung Cancer; Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor; Recurrent Breast Cancer; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Cell Lung Cancer; Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor; Stage IV Breast Cancer; Stage IV Melanoma; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib; Drug: paclitaxel; Drug: carboplatin; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Dystonia Coalition Projects

Conditions: Dystonia; Voice Disorders
Intervention:
Sponsors: Emory University; Hyder A. Jinnah, MD, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Office of Rare Diseases (ORD); Allergan; Dystonia Study Group
Recruiting - verified May 2013
The Evaluation of VAD InterVEntion Before Inotropic Therapy

Condition: Congestive Heart Failure
Interventions: Device: HM II® (HeartMate II® LVAD); Other: OMM (Optimal Medical Management)
Sponsors: University of Michigan; University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); Thoratec Corporation
Not yet recruiting - verified May 2013
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified May 2013
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2013
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812)
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified May 2013
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified April 2013
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis

Conditions: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With Ccr5 Tropic HIV 1

Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2013
Hydrocortisone for BPD

Conditions: Infant, Newborn; Infant, Small for Gestational Age; Infant, Very Low Birth Weight; Infant, Premature; Bronchopulmonary Dysplasia
Interventions: Drug: Hydrocortisone; Drug: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified May 2013
A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified April 2013
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2013
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013
Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis

Condition: Graft Versus Host Disease (GVHD)
Interventions: Procedure: extracorporeal photopheresis; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified April 2013
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified April 2013
Open-Label Extension Study of GSK1605786A

Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: Placebo; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Condition: Depression
Interventions: Drug: Armodafinil; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified April 2013
INcrease Of VAgal TonE in CHF

Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

Condition: Colorectal Cancer Metastatic
Interventions: Drug: Regorafenib (BAY 73-4506); Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Bayer
Recruiting - verified April 2013
A Phase 1 Study of LY2787106 in Cancer and Anemia

Condition: Anemia
Interventions: Drug: LY2787106; Dietary Supplement: Iron Supplementation
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of Modified Stem Cells in Stable Ischemic Stroke

Condition: Chronic Ischemic Stroke
Intervention: Biological: SB623
Sponsors: SanBio, Inc.; SanBio, Inc.
Recruiting - verified May 2013
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Conditions: Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Biological: wild-type reovirus; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

Conditions: Neoplasms; Lymphomas
Intervention: Drug: Belinostat
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2012
A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: Everolimus; Drug: Pasireotide; Drug: Everolimus and Pasireotide
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified May 2013
Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol for oral suspension placebo proxy; Drug: Welchol for oral suspension
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified May 2013
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

Condition: Epilepsy
Interventions: Drug: Placebo; Drug: Brivaracetam; Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM3)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Conditions: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: bicalutamide; Other: clinical observation
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Conditions: Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Spinal Cord Neoplasm; Untreated Childhood Brain Stem Glioma; Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat; Biological: bevacizumab; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza.

Condition: Influenza, Human
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Alzheimer's Disease Neuroimaging Initiative 2

Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2013
A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease

Condition: Alzheimer Disease
Interventions: Drug: gantenerumab; Drug: gantenerumab; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study of Everolimus (RAD001)in Combination With Lenalidomide

Condition: Solid Organ Malignancies
Interventions: Drug: Lenalidomide; Drug: Everolimus
Sponsors: Emory University; Emory University; Celgene Corporation; Novartis
Recruiting - verified May 2013
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2013
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified May 2013
Post-Myocardial Infarction Remodeling Prevention Therapy

Conditions: Acute Myocardial Infarction; Pacing Therapy; Cardiac Remodeling; Heart Failure
Interventions: Device: Single Site Pacing; Device: Dual Site Pacing
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Cardiac Rhythm Disease Management
Recruiting - verified May 2013
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

Conditions: Disseminated Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4S Neuroblastoma
Interventions: Drug: vorinostat; Drug: isotretinoin; Other: diagnostic laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Pharmacogenomic Evaluation of Antihypertensive Responses 2

Condition: Hypertension
Intervention: Drug: metoprolol or chlorthalidone
Sponsors: National Institute of General Medical Sciences (NIGMS); National Institute of General Medical Sciences (NIGMS)
Recruiting - verified May 2013
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Conditions: AML; ALL; Blast Crisis; MDS; Multiple Myeloma
Intervention: Drug: TG02 citrate
Sponsors: Tragara Pharmaceuticals, Inc.; Tragara Pharmaceuticals, Inc.
Recruiting - verified May 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Sorafenib
Sponsors: Emory University; Emory University; Onyx Pharmaceuticals; Bayer
Recruiting - verified May 2013
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Condition: Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Temozolomide; Radiation: Irradiation
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Children's Hospital Boston; University of California, San Francisco; Ann & Robert H Lurie Children's Hospital of Chicago; Children's Healthcare of Atlanta; Children's Hospital Colorado; Children's Hospital Los Angeles; Children's Hospital of Michigan; Children's Hospitals and Clinics of Minnesota; Cook Children's Medical Center; Doernbecher Children's Hospital; Duke University; Johns Hopkins University; Memorial Sloan-Kettering Cancer Center; Miami Children's Hospital; New York University; Penn State Hershey Medical Center; Seattle Children's; University of Louisville; University of Mississippi Medical Center; UT Southwestern Medical Center; Washington University Medical Center
Recruiting - verified May 2013
Nephrotic Syndrome Study Network

Conditions: Minimal Change Disease (MCD); Membranous Nephropathy; Glomerulosclerosis, Focal Segmental
Intervention:
Sponsors: University of Michigan; University of Michigan; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The NephCure Foundation
Recruiting - verified April 2013
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

Conditions: Pancreatic Neoplasms; Pancreatic Cancer
Interventions: Drug: Gemcitabine and cisplatin; Drug: Gemcitabine / Cisplatin
Sponsors: Emory University; Emory University
Recruiting - verified May 2013
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

Condition: Cytomegalovirus Infections, Heart Transplantation
Intervention: Drug: valganciclovir [Valcyte]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Aliskiren; Drug: Aliskiren
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: Aripiprazole; Drug: Aripiprazole
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013
A Trial of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone in Patients With ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary PCI

Conditions: Acute Coronary Syndrome; ST Elevation Myocardial Infarction; Percutaneous Coronary Intervention
Intervention: Procedure: Percutaneous Coronary Intervention with or without manual aspiration thrombectomy
Sponsors: Population Health Research Institute; Population Health Research Institute
Recruiting - verified May 2013
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Metastatic Intraocular Melanoma; Recurrent Intraocular Melanoma
Interventions: Drug: selumetinib; Drug: temozolomide; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Childhood Cancer Survivor Study

Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center; Nationwide Children's Hospital; M.D. Anderson Cancer Center; University of Southern California; Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2013
A Study in Patients With Diabetic Kidney Disease

Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Condition: Peripheral T-cell Lymphoma
Intervention:
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013
Patient Registry Study of Berinert® in Normal Clinical Practice

Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2013
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Selexipag (ACT-293987); Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen

Condition: Lymphoma, Follicular
Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A); Drug: Bendamustine infusion (Arm B)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
Evaluation of the Artus® CMV PCR Test

Condition: Cytomegalovirus Infections
Intervention:
Sponsors: QIAGEN Gaithersburg, Inc; QIAGEN Gaithersburg, Inc
Recruiting - verified April 2013
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Vorinostat; Radiation: 131- I Metaiodobenzylguanidine; Procedure: Peripheral Blood Stem Cell Infusion; Drug: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2013
Red Cell Storage Duration Study

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Interventions: Biological: Red blood cell units stored <= 10 days; Biological: Red blood cell units stored >= 21 days
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Prostate Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: cisplatin; Other: placebo; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial

Condition: Childhood Cancers
Interventions: Behavioral: P-SCIP; Behavioral: BPC
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; Children's Hospital Los Angeles; Columbia University; Emory University; Memorial Sloan-Kettering Cancer Center; Mount Sinai School of Medicine; Weill Medical College of Cornell University; Triad Interactive; National Marrow Donor Program
Recruiting - verified May 2013
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified May 2013
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

Conditions: Graft Rejection; Kidney Transplant; Renal Allograft Recipients; Renal Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Tacrolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

Condition: HIV-1
Intervention: Drug: No drug will be administered
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Progesterone for the Treatment of Traumatic Brain Injury

Condition: Traumatic Brain Injury
Intervention: Drug: Progesterone
Sponsors: Emory University; David Wright
Recruiting - verified May 2013
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Conditions: Multiple Myeloma; Plasma Cell Neoplasm
Interventions: Drug: Group A=30-60 CrCl (mL/min); Drug: Group B=CrCL<30 mL/min not on dialysis; Drug: Group C=CrCL<30 mL/min and on dialysis
Sponsors: PrECOG, LLC.; PrECOG, LLC.; Celgene Corporation
Recruiting - verified May 2013
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013
Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease

Condition: Degenerative Disc Disease (DDD)
Interventions: Device: FLD; Device: Control
Sponsors: AxioMed Spine Corporation; AxioMed Spine Corporation
Recruiting - verified May 2013
Study To Assess The Safety, Pharmacokinetics, And Evaluate The Response To Anidulafungin When Treating Children With Invasive Candidiasis

Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified October 2012
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Clindamycin; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013
Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified April 2013
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified April 2013
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: prednisone; Drug: thalidomide; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab; Drug: No Biologics
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.

Condition: Influenza
Interventions: Drug: oseltamivir; Drug: oseltamivir; Other: Alternative Control
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Conditions: Gastroesophageal Junction Adenocarcinoma; Gastric Cancer
Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Sanofi; Roche/Genetech; City of Hope National Medical Center; Piedmont Hospital Research Institute; Medical College of Wisconsin; Queens Health Network; Weill Medical College of Cornell University; Memorial Cancer Institute, Florida; University of Pittsburgh; Long Island Jewish Medical Center; Nebraska Cancer Specialists Methodist Estabrook Cancer Center
Recruiting - verified April 2013
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: adult human mesenchymal stem cells; Drug: Placebo
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2013
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Advanced Gastric Cancer; Advanced/Metastatic Non-small Cell Lung Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastatic Castration-resistant Prostate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2013
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer

Conditions: Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
Interventions: Biological: ziv-aflibercept; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2013
Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.

Conditions: Seizures; Epilepsies, Partial; Epilepsy, Complex Partial; Epilepsy, Generalized; Epilepsy
Interventions: Drug: Placebo; Drug: Vanquix Auto-Injector (Diazepam Injection)
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Study Evaluating CMC-544 Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin; Drug: inotuzumab ozogamicin; Drug: inotuzumab ozogamicin
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: cyclophosphamide; Drug: prednisone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); Cancer Institute of New Jersey; Columbia University; Winship Cancer Institute of Emory University
Recruiting - verified May 2013
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); NCIC Clinical Trials Group
Recruiting - verified May 2013
Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment

Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013

Find Paid Research Studies in Atlanta, Georgia

Welcome to Paid Research Studies.